Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study

Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis : a prospective, open-label, multi-centre study

Rombo, Lars (författare): Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Med Solna, Infect Dis Unit, SE-17176 Stockholm, Sweden

Hallén, Ingemar (författare): Karlstad Cty Hosp, Dept Infect Dis, SE-65185 Karlstad, Sweden

Thörner, Åke (författare): Malar Hosp, Dept Rheumatol, SE-63188 Eskilstuna, Sweden

Nordin, Margareta (författare): Karolinska Univ Hosp, Dept Clin Microbiol, SE-17176 Stockholm, Sweden

Herzog, Christian (författare): Swiss Trop & Publ Hlth Inst, CH-4051 Basel, Switzerland

(creator_code:org_t)

Elsevier BV, 2014
2014
Engelska.
Ingår i: Travel Medicine and Infectious Disease. - : Elsevier BV. - 1477-8939 .- 1873-0442. ; 12:2, s. 134-42

Relaterad länk:: https://uu.diva-port... (primary) (Raw object); visa fler...; https://doi.org/10.1...; https://urn.kb.se/re...; https://doi.org/10.1...; http://kipublication...; visa färre...

Abstract Ämnesord

Stäng

BACKGROUND: Hepatitis A vaccine is the most frequently used travel vaccine, yet data are scarce about its ability to induce protection in patients with concurrent immunosuppressive treatment. We assessed the immunogenicity of this vaccine in rheumatoid arthritis (RA) patients treated with tumour necrosis factor-inhibitors (TNFi) and/or methotrexate (MTX).METHODS: Hepatitis A vaccine was administered to non-immune RA patients at 0 and 6 months. Hepatitis A virus (HAV) antibodies were assessed at 0, 1, 6, 7, 12, and 24 months with a quantitative Chemiluminescent Microparticle Immuno Assay (CMIA) for HAV-IgG. Samples from month 1, 6, and 7 were, in addition, analysed with a microparticle EIA (MEIA) for anti-HAV IgM + IgG.RESULTS: The final study population consisted of 53 patients treated with TNFi (n = 15), TNFi + MTX (n = 21) or MTX (n = 17). One and six months after the first dose, 10% and 33% of the patients had attained seroprotection. One and six months after the second dose 83% and 72% were seroprotected. At month 24, 86% of the vaccinees showed protective levels.CONCLUSIONS: Two doses of hepatitis A vaccine at a 6-month interval provided protection for most immunosuppressed RA patients. A single dose does not seem to afford sufficient protection to this group of patients.

Av författaren/redakt...: Askling, Helena ...; Rombo, Lars; van Vollenhoven, ...; Hallén, Ingemar; Thörner, Åke; Nordin, Margaret ...; visa fler...; Herzog, Christia ...; Kantele, Anu; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Infektionsmedici ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.